S.S.M. has received consulting and advisory fees from 89bio, Akcea, Amgen, Astra Zeneca, Esperion, Kaneka, Novo Nordisk, Quest Diagnostics, Sanofi, Regeneron and REGENXBIO and funding from Amgen. M.P.T. has received funding from Apple, AstraZeneca and Boehringer Ingelheim, consulting fees ...
All these factors should be incorporated into the decision-making process aiming for the most effective treatment regimen which is also safe and well-tolerated and supports good quality of life. 6.1. Disease Based Decision Factors For difficult-to-treat patient subsets, such as extramedullary disease...